514 related articles for article (PubMed ID: 33716705)
21. Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease.
Ledonne A; Massaro Cenere M; Paldino E; D'Angelo V; D'Addario SL; Casadei N; Nobili A; Berretta N; Fusco FR; Ventura R; Sancesario G; Guatteo E; Mercuri NB
Mov Disord; 2023 Feb; 38(2):256-266. PubMed ID: 36350188
[TBL] [Abstract][Full Text] [Related]
22. Dopamine midbrain neurons in health and Parkinson's disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels.
Dragicevic E; Schiemann J; Liss B
Neuroscience; 2015 Jan; 284():798-814. PubMed ID: 25450964
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of Pacemaker Activity in Zebrafish DC2/4 Dopaminergic Neurons.
Ilin VA; Bai Q; Watson AM; Volgushev M; Burton EA
J Neurosci; 2021 May; 41(18):4141-4157. PubMed ID: 33731451
[TBL] [Abstract][Full Text] [Related]
24. Calcium homeostasis, selective vulnerability and Parkinson's disease.
Chan CS; Gertler TS; Surmeier DJ
Trends Neurosci; 2009 May; 32(5):249-56. PubMed ID: 19307031
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of L-Type Ca
Sun Y; Zhang H; Selvaraj S; Sukumaran P; Lei S; Birnbaumer L; Singh BB
J Neurosci; 2017 Mar; 37(12):3364-3377. PubMed ID: 28258168
[TBL] [Abstract][Full Text] [Related]
26. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
27. Extracellular S100B inhibits A-type voltage-gated potassium currents and increases L-type voltage-gated calcium channel activity in dopaminergic neurons.
Bancroft EA; De La Mora M; Pandey G; Zarate SM; Srinivasan R
Glia; 2022 Dec; 70(12):2330-2347. PubMed ID: 35916350
[TBL] [Abstract][Full Text] [Related]
28. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
Ahlers-Dannen KE; Spicer MM; Fisher RA
Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
[TBL] [Abstract][Full Text] [Related]
29. Robust pacemaking in substantia nigra dopaminergic neurons.
Guzman JN; Sánchez-Padilla J; Chan CS; Surmeier DJ
J Neurosci; 2009 Sep; 29(35):11011-9. PubMed ID: 19726659
[TBL] [Abstract][Full Text] [Related]
30. Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.
Guzman JN; Ilijic E; Yang B; Sanchez-Padilla J; Wokosin D; Galtieri D; Kondapalli J; Schumacker PT; Surmeier DJ
J Clin Invest; 2018 Jun; 128(6):2266-2280. PubMed ID: 29708514
[TBL] [Abstract][Full Text] [Related]
31. The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson's Disease.
Caulfield ME; Manfredsson FP; Steece-Collier K
Handb Exp Pharmacol; 2023; 279():107-137. PubMed ID: 36592226
[TBL] [Abstract][Full Text] [Related]
32. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
Chang CC; Cao S; Kang S; Kai L; Tian X; Pandey P; Dunne SF; Luan CH; Surmeier DJ; Silverman RB
Bioorg Med Chem; 2010 May; 18(9):3147-58. PubMed ID: 20382537
[TBL] [Abstract][Full Text] [Related]
33. Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
Kang S; Cooper G; Dunne SF; Luan CH; James Surmeier D; Silverman RB
Bioorg Med Chem; 2013 Jul; 21(14):4365-73. PubMed ID: 23688558
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical localization of voltage-gated calcium channels in substantia nigra dopamine neurons.
Takada M; Kang Y; Imanishi M
Eur J Neurosci; 2001 Feb; 13(4):757-62. PubMed ID: 11207810
[TBL] [Abstract][Full Text] [Related]
35. Somatodendritic ion channel expression in substantia nigra pars compacta dopaminergic neurons across postnatal development.
Dufour MA; Woodhouse A; Goaillard JM
J Neurosci Res; 2014 Aug; 92(8):981-99. PubMed ID: 24723263
[TBL] [Abstract][Full Text] [Related]
36. Gating of dopamine transmission by calcium and axonal N-, Q-, T- and L-type voltage-gated calcium channels differs between striatal domains.
Brimblecombe KR; Gracie CJ; Platt NJ; Cragg SJ
J Physiol; 2015 Feb; 593(4):929-46. PubMed ID: 25533038
[TBL] [Abstract][Full Text] [Related]
37. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.
Surmeier DJ; Guzman JN; Sanchez-Padilla J
Cell Calcium; 2010 Feb; 47(2):175-82. PubMed ID: 20053445
[TBL] [Abstract][Full Text] [Related]
38. Voltage-operated Ca2+ channels regulate dopamine release from somata of dopamine neurons in the substantia nigra pars compacta.
Kim Y; Park MK; Chung S
Biochem Biophys Res Commun; 2008 Sep; 373(4):665-9. PubMed ID: 18601902
[TBL] [Abstract][Full Text] [Related]
39. Regulation of somatodendritic dopamine release by corticotropin-releasing factor via the inhibition of voltage-operated Ca2+ channels.
Kim Y; Park MK; Chung S
Neurosci Lett; 2009 Nov; 465(1):31-5. PubMed ID: 19729048
[TBL] [Abstract][Full Text] [Related]
40. Calcium and Parkinson's disease.
Surmeier DJ; Schumacker PT; Guzman JD; Ilijic E; Yang B; Zampese E
Biochem Biophys Res Commun; 2017 Feb; 483(4):1013-1019. PubMed ID: 27590583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
